Pharmacology of Chinese Herbal Medicine (Ongoing)

Posted On 2021-07-05 16:20:46



The series on “Pharmacology of Chinese Herbal Medicine” is edited by Dr. Zhi-Xiu Lin (Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.), Dr. Hong-Xi Xu (School of Pharmacy, Shanghai University of Chinese Medicine, Shanghai, China.) and Dr. Yan-Fang Xian (School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.)

Zhi-Xiu Lin
Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

Professor Lin graduated from Guangzhou University of Chinese Medicine in 1987 with a BSc in Chinese Medicine. After graduation, he worked as a Chinese medicine doctor at the Affiliated Hospital of Guangdong Provincial Research Institute of Chinese Medicine. In 1991 he moved to England to study English language, followed by a PhD degree study at the Department of Pharmacy, King College, University of London. He obtained his PhD degree in Pharmacognosy in 1999. From 1998 to 2002, he was employed as a Senior Lecturer and Programme Leader on the Chinese Medicine Programme, Middlesex University in London where he was involved with basic and clinical teachings of Chinese medicine. Professor Lin joined The Chinese University of Hong Kong in 2003, and is now Professor and Associate Director of the School. His main research interests include: (1). Pharmacological studies on Chinese medicines for psoriasis, eczema, pancreatic cancer and Neuroprotection; (2). Systematic evaluation of the effectiveness of Chinese medicine treatment for some common diseases; and (3). Clinical trial on effectiveness and safety of acupuncture for post-stroke dysphagia and overactive bladder. Over the years, he has published over 210 research articles on Chinese medicine, among them, about 190 articles are in the SCI journals.

Hong-Xi Xu
School of Pharmacy, Shanghai University of Chinese Medicine, Shanghai, China.

Professor Hong-Xi Xu has studied and worked abroad for more than 20 years. He has been actively involved in Chinese medicine research in various institutions in Japan, Singapore, Canada and Hong Kong. He has been appointed as a distinguished professor of Shanghai University of Traditional Chinese Medicine since 2011 and is currently the Dean of the School of Pharmacy. In recognition of his achievements, Professor Xu was selected as a “Specially-Appointed Professor of Shanghai”. Prof. Xu has published more than 320 SCI papers. H index is 56. His current research interest is focused on new drug discovery from natural resources, as well as the development of botanical dietary supplements from herbal medicines. Specifically, he is interested in finding natural lead compounds from medicinal plants and in developing new drug based on Chinese medicines against different disease targets such as cancer, HSV, and metabolic diseases. He applies multiple assay models targeting cell death (e.g. apoptosis, autophagy), metastasis, and quiescent cell recurrence to screen for anti-cancer natural compounds. With state-of-the-art technologies, he investigates the in vitro and in vivo mechanisms of action of the novel compounds from medicinal plants.

Yan-Fang Xian
School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

Dr. Xian graduated from Guangzhou University of Chinese Medicine in 2004 and 2007 with a BSc and MPhil degrees in Chinese Medicine. She obtained her PhD degree in Chinese Medicine in 2013 from The Chinese University of Hong Kong. From 2013 to 2017, she was employed as a Postdoctoral Fellow at School of Chinese Medicine, the Chinese University of Hong Kong. Dr. Xian is now the Research Assistant Professor at School of Chinese Medicine, The Chinese University of Hong Kong since 2017. Her main research interests include: (1). Pharmacological studies on Chinese medicines for Neuroprotection and cancer; (2). Systematic evaluation of the effectiveness of Chinese medicine treatment for some common diseases; and (3). The toxicity study of Chinese medicines. Over the years, she has published over 76 research articles on Chinese medicine; among them, about 67 articles are in the SCI journals.

Series outline:

  1. Chinese Medicine Against the COVID-19: Current Status, Challenge and Perspectives
  2. Clinical Studies of Several Famous and Precious Herbal Medicines
  3. An Urge to Improve the Pharmacy Management of Chinese Medicine: An Overture of Good Pharmacy Practice (GPP) for Pharmacy of Chinese Medicine in Hong Kong
  4. The Neuroprotective Activities of Icariin in the Rodent Models of Alzheimer's Disease: A Systematic Review
  5. Cardiotoxicity of Cinnabar
  6. Current Progress of Chinese Medicine for Neurogenesis and Its Application for Functional Recovery in Post-stroke Treatment

Disclosure:
The series “Pharmacology of Chinese Herbal Medicine” was commissioned by the editorial office, Longhua Chinese Medicine without any sponsorship or funding. Zhi-Xiu Lin, Hong-Xi Xu and Yan-Fang Xian are serving as the unpaid Guest Editors for the series.